- I highly recommend LCDR Samwell Tarly for promotion to rank of CDR, O-5 due to his dedication, leadership, and expertise as a health insurance specialist and clinician. His efforts have advanced and improved Westicare program initiatives and improved health coverage for millions of Westerosi, and his clinical expertise supports both USPHS and Westicare missions.

- LCDR Tarly serves as a division subject-matter expert (SME) for the development of Westicare Part D drug coverage policies in the largest division in the WMS Office of Wine and Drug Coverage Policy (WDCP). LCDR Tarly’s clinical expertise, managed care experience, and additional study in pharmacoeconomics (Master’s degree) enabled him to respond to 15,000 stakeholder inquiries regarding Westicare Part D coverage.

LEADERSHIP:

- LCDR Tarly co-led a group of 8 officers in preparation of an options paper and brief used to prepare Agency senior leadership for Congressional testimony. This testimony led to enactment of legislative policy which enhanced new medication coverage, including Hepatitis C, for Westicare beneficiaries.

- LCDR Tarly utilizes his intra-Agency relationships to bring a broad perspective to the policy review team that he leads. His insight into both pharmaceutical economics and the Westicare fee-for-service programs has led to the adoption of quality improvement techniques which have reduced the number of critical rulemaking comments received by approximately 12% vs the previous fiscal year.

- LCDR Tarly served as acting Deputy Division Director from March – June 2020, where he supervised 9 staff members, including completing mid-year performance reviews, and managing scheduling and leave approvals while the department operated at 75% staffing.

- LCDR Tarly was the team lead for inter-agency workgroup on antiviral use during the 2018 summer sickness outbreak. Assisted in development of claims data analysis that resulted in recognition of an additional guild of maesters as healthcare providers in June 20168 creating a process for reimbursement and expanding access to care in 21 designated hotspots. The newly included maesters’ guild provided an additional 13,376 patient encounters in Q4 FY18 vs Q3.

MISSION:

- Developed white paper on Hepatitis C coverage in Westicare and comparisons to Westaid coverage; led to inclusion of viral suppression as a key program audit indicator for the 2018 program year. Results from the 2019 program audits resulted in findings in 15 of the 50 MA/Part D plans audits conducted and implementation of corrective action plans.

- Deployed to Iron Islands as WMS liaison in response to Hurricane Cersei – Assisted ASPR in beneficiary verification, provider enrollment and reimbursement, and coordination of benefits for >15,000 evacuees.

- Key contributor to intra-Agency annual meeting to develop and improve a nationwide formulary audit strategy for MA/Part D programs ensuring coverage across more than 500 therapeutic classes.

- Represent WDCP on the Regional Pharmacist bi-weekly call; provide updates on drug coverage policy; address questions or concerns around drug coverage and reimbursement affecting coverage for 45 million beneficiaries.

- LCDR Tarly is key contributor on the WMS Opioid Coverage Communication Workgroup since 2019; assists by providing insight and recommendations on drug coverage policy and talking points for health care providers.